HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: clinchem.2008.121236v1 55/7/1347    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Google Scholar Articles by Niizuma, S. Articles by Miyazaki, S. PubMed PubMed Citation Articles by Niizuma, S. Articles by Miyazaki, S.

Impact of Left Ventricular End-Diastolic Wall Stress on Plasma B-Type Natriuretic Peptide in Heart Failure with Chronic Kidney Disease and End-Stage Renal Disease

¹ Division of Hypertension and Nephrology; and ² Division of Cardiology, National Cardiovascular Center, Suita, Japan; ³ Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; ⁴ Division of Cardiology, Department of Internal Medicine, Kinki University School of Medicine, Osakasayama, Japan.

^aAddress correspondence to this author at: Division of Cardiology, Department of Internal Medicine, Kinki University School of Medicine, 377–2 Ohno-Higashi, Osakasayama 589-8511, Japan. Fax +81-72-368-2378; e-mail yiwanaga{at}med.kindai.ac.jp.

Background: Plasma B-type natriuretic peptide (BNP) is a diagnostic and prognostic marker in heart failure (HF). Although renal function is reported as an important clinical determinant, precise evaluations of the relationships of renal function with hemodynamic factors in determining BNP have not been performed. Therefore, we evaluated the association of plasma BNP concentrations with LV end-diastolic wall stress (EDWS) in a broad range of HF patients including those with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

Methods: In 156 consecutive HF patients including those with CKD and ESRD, we measured plasma BNP and performed echocardiography and cardiac catheterization. LV EDWS was calculated as a crucial hemodynamic determinant of BNP.

Results: Plasma BNP concentrations increased progressively with decreasing renal function across the groups (P < 0.01) and were correlated with LV EDWS (r = 0.47) in the HF patients overall. This relationship was also present when patients were subdivided into systolic and diastolic HF (P < 0.01). In multivariable analysis, higher EDWS was associated with increased BNP concentration independently of renal dysfunction (P < 0.01). Anemia, systolic HF, and decreased BMI also contributed to increased BNP concentrations.

Conclusions: These results suggest that LV EDWS is a strong determinant of BNP even in patients with CKD and ESRD. Anemia, obesity, and HF type (systolic or diastolic) should also be considered in interpreting plasma BNP concentrations in HF patients. These findings may contribute to the clinical management of HF patients, especially those complicated with CKD and ESRD.

The following articles in journals at HighWire Press have cited this article:

				C. R. deFilippi and R. H. Christenson B-Type Natriuretic Peptide (BNP)/NT-proBNP and Renal Function: Is the Controversy Over? Clin. Chem., July 1, 2009; 55(7): 1271 - 1273. [Full Text] [PDF]